ATS View
한국어

Samil Pharmaceutical KRX:000520KOSPI

삼일제약 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked22since Sep 11

In Q2 2026, Samil Pharmaceutical reported revenue of ₩50.6bn, down 5.9% year on year, and an operating loss of ₩6.3bn. Samil Pharmaceutical (삼일제약) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Oct 21 with 1 article.

Filing signals Insider buying 4 quarters of losses Share pledge Screener

Samil Pharmaceutical quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩50.6bn-5.9%−₩6.3bn
margin −12.5%		−₩7.7bn
Q1 2026₩52.5bn+0.5%−₩8.4bn
margin −15.9%		−₩10.8bn
Q4 2025 derived₩53.0bn-8.3%−₩8.6bn
margin −16.2%		−₩11.2bn
Q3 2025₩51.2bn-4.0%−₩5.2bn
margin −10.1%		−₩7.9bn
Q2 2025₩53.8bn-0.9%−₩3.1bn
margin −5.8%		−₩6.5bn
Q1 2025₩52.3bn-3.7%−₩5.4bn
margin −10.3%		−₩9.1bn
Q4 2024 derived₩57.8bn+14.4%−₩2.9bn
margin −4.9%		−₩3.6bn
Q3 2024₩53.3bn+3.3%−₩240m
margin −0.4%		−₩676m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Samil Pharmaceutical top stories 2 weeks, by number of outlets

  1. 1
    삼일제약 베트남 공장, 본격 가동 막바지…KGMP 인증만 남겨
    1 outlets · 1 articlesFirst report Oct 21 06:02 메디파나뉴스
  2. 2
    삼일제약 ‘모노프로스트’, 보존제 독성 덜고 안압 강하 입증 … 녹내장 1차 표준 치료 정조준
    1 outlets · 1 articlesFirst report Oct 28 01:22 헬스코리아뉴스

Latest Samil Pharmaceutical news Korean headlines